Actively Recruiting

Age: 40Years - 85Years
All Genders
NCT04761393

Characterizing Matrix Metalloproteinase-12 (MMP12) in Sputum

Led by McMaster University · Updated on 2024-11-20

45

Participants Needed

1

Research Sites

109 weeks

Total Duration

On this page

Sponsors

M

McMaster University

Lead Sponsor

F

Foresee Pharmaceuticals Co., Ltd.

Collaborating Sponsor

AI-Summary

What this Trial Is About

The hypothesis is that in patients with emphysema, a high MMP12 sputum and/or blood level correlates with airspace enlargement and with increased sputum Th2 immune biomarkers.

CONDITIONS

Official Title

Characterizing Matrix Metalloproteinase-12 (MMP12) in Sputum

Who Can Participate

Age: 40Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 40 years or older
  • Current or former smokers with more than 10 pack years smoking history
  • Post-bronchodilator FEV1/FVC ratio less than 70% and post-bronchodilator FEV1 of 30% predicted or higher (GOLD 1, 2, and 3)
  • Radiologist confirmed emphysema diagnosis based on CT scan
  • For normal controls: no significant medical or respiratory conditions, no smoking history, and post-bronchodilator FEV1/FVC ratio greater than 70%
Not Eligible

You will not qualify if you...

  • Presence of non-COPD airway diseases
  • Very severe COPD with FEV1 less than 30% predicted
  • Current exacerbation of lung disease
  • Life expectancy less than 3 months
  • Pregnancy or breastfeeding
  • Receiving immunomodulatory or biologic treatments
  • Use of systemic steroids in the last month
  • Hospitalization due to exacerbation in the past 12 months
  • Known cardiovascular disease under treatment or hospitalization in the past year
  • Unable to perform spirometry
  • Active cancer
  • Lung surgery during the study period
  • History of alcohol or drug abuse affecting study compliance
  • History of bronchial thermoplasty
  • Participation in another clinical study simultaneously
  • Presence of implanted devices or metal in the body incompatible with MRI, such as pacemakers, artificial limbs, metallic fragments, shunts, surgical staples, or ear implants

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Firestone Institute for Respiratory Health, St. Joseph's Healthcare

Hamilton, Ontario, Canada, L8N 4A6

Actively Recruiting

Loading map...

Research Team

S

Sarah Svenningsen, PhD

CONTACT

M

Melanie Kjarsgaard

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Characterizing Matrix Metalloproteinase-12 (MMP12) in Sputum | DecenTrialz